Wegovy maker Novo Nordisk agreed to acquire metabolic biotech Akero Therapeutics (Nasdaq: AKRO) for up to $5.2 billion in cash.
Why it matters: It's the first deal led by new Novo CEO Mike Doustdar, and comes as the Danish pharma giant faces heightened competition from rival Eli Lilly.
